Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis

 

 Buy Article Permissions and Reprints

Abstract

In addition to a high prevalence of the metabolic syndrome and a significant under-diagnosis of vascular risk factors (VRFs), the effect of chronic inflammation also represents the cornerstone of the raised cardiovascular (CV) risk in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Moreover, the finding that among current anti-inflammatory treatments, the use of tumor necrosis factor (TNF)-α blockers is associated with optimal rheumatologic and CV outcomes further supports the impact of inflammation on the CV risk. However, up-to-date treatment guidelines suggest that TNF-α blockers should be used only after the failure of traditional disease-modifying antirheumatic drugs (DMARDs). Early predictors of the therapeutic efficacy of traditional DMARDs are needed to identify candidates for TNF-α blocker treatment. Furthermore, whether the CV risk should be taken into account while choosing antirheumatic treatments is an emerging issue to be addressed. Common educational programs for specialists and general practitioners and appropriate CV prevention programs, taking into consideration traditional VRFs as well as the inflammatory status, should be planned to prevent ischemic events and to achieve optimal inflammation control in rheumatic patients.

• References

• 1 Peters MJ, Symmons DP, McCarey D , et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69 (2) 325-331
  CrossrefPubMedGoogle Scholar
• 2 Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010; 30 (5) 1014-1026
  CrossrefPubMedGoogle Scholar
• 3 Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108 (24) 2957-2963
  CrossrefPubMedGoogle Scholar
• 4 del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44 (12) 2737-2745
  CrossrefPubMedGoogle Scholar
• 5 van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65 (12) 1551-1557
  CrossrefPubMedGoogle Scholar
• 6 Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66 (9) 1132-1136
  CrossrefPubMedGoogle Scholar
• 7 Popa C, van den Hoogen FH, Radstake TR , et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66 (11) 1503-1507
  CrossrefPubMedGoogle Scholar
• 8 Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247 (3) 349-358
  CrossrefPubMedGoogle Scholar
• 9 Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34 (3) 585-592
  CrossrefPubMedGoogle Scholar
• 10 Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11 (8) 327-332
  CrossrefPubMedGoogle Scholar
• 11 Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19 (4) 972-978
  CrossrefPubMedGoogle Scholar
• 12 Solomon DH, Karlson EW, Rimm EB , et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107 (9) 1303-1307
  CrossrefPubMedGoogle Scholar
• 13 Liang KP, Kremers HM, Crowson CS , et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009; 36 (11) 2462-2469
  CrossrefPubMedGoogle Scholar
• 14 Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010; 69 (9) 1649-1654
  CrossrefPubMedGoogle Scholar
• 15 Aho K, Salonen JT, Puska P. Autoantibodies predicting death due to cardiovascular disease. Cardiology 1982; 69 (3) 125-129
  CrossrefPubMedGoogle Scholar
• 16 Karvounaris SA, Sidiropoulos PI, Papadakis JA , et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007; 66 (1) 28-33
  PubMedGoogle Scholar
• 17 Chung CP, Oeser A, Solus JF , et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196 (2) 756-763
  CrossrefPubMedGoogle Scholar
• 18 Toms TE, Panoulas VF, Douglas KM , et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010; 69 (4) 683-688
  CrossrefPubMedGoogle Scholar
• 19 Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53 (8) 551-552
  CrossrefPubMedGoogle Scholar
• 20 Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; 8 (3) 301-326
  CrossrefPubMedGoogle Scholar
• 21 Panoulas VF, Metsios GS, Pace AV , et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47 (9) 1286-1298
  CrossrefPubMedGoogle Scholar
• 22 Klarenbeek NB, van der Kooij SM, Huizinga TJ , et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010; 69 (7) 1342-1345
  CrossrefPubMedGoogle Scholar
• 23 Panoulas VF, Douglas KM, Milionis HJ , et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (9) 1477-1482
  CrossrefPubMedGoogle Scholar
• 24 Provan SA, Semb AG, Hisdal J , et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis Feb. 2011; 70: 812-817
  PubMedGoogle Scholar
• 25 Mäki-Petäjä KM, Hall FC, Booth AD , et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114 (11) 1185-1192
  CrossrefPubMedGoogle Scholar
• 26 Tanaka K, Inaba M, Goto H , et al. Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol 2006; 33 (4) 652-658
  PubMedGoogle Scholar
• 27 Pieringer H, Schumacher S, Stuby U, Biesenbach G. Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin Arthritis Rheum 2009; 39 (3) 163-169
  CrossrefPubMedGoogle Scholar
• 28 Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82 (6) 407-413
  CrossrefPubMedGoogle Scholar
• 29 Park YB, Ahn CW, Choi HK , et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46 (7) 1714-1719
  CrossrefPubMedGoogle Scholar
• 30 Kumeda Y, Inaba M, Goto H , et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46 (6) 1489-1497
  CrossrefPubMedGoogle Scholar
• 31 Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2011; Oct 27. DOI: 10.1016/j.semarthrit.2011.08.003
  PubMedGoogle Scholar
• 32 Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis?. Platelets 2008; 19 (2) 146-154
  CrossrefPubMedGoogle Scholar
• 33 Wang F, Wang NS, Yan CG, Li JH, Tang LQ. The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol 2007; 26 (5) 768-771
  CrossrefPubMedGoogle Scholar
• 34 Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events. Semin Thromb Hemost 2010; 36 (4) 452-457
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 So AK, Varisco PA, Kemkes-Matthes B , et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1 (12) 2510-2515
  CrossrefPubMedGoogle Scholar
• 36 Undas A, Gissel M, Kwasny-Krochin B, Gluszko P, Mann KG, Brummel-Ziedins KE. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost 2010; 104 (2) 224-230
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59 (12) 1690-1697
  CrossrefPubMedGoogle Scholar
• 38 Peters MJ, van Halm VP, Voskuyl AE , et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61 (11) 1571-1579
  CrossrefPubMedGoogle Scholar
• 39 Douglas KM, Pace AV, Treharne GJ , et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65 (3) 348-353
  CrossrefPubMedGoogle Scholar
• 40 Maradit-Kremers H, Crowson CS, Nicola PJ , et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52 (2) 402-411
  CrossrefPubMedGoogle Scholar
• 41 Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34 (5) 937-942
  PubMedGoogle Scholar
• 42 Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H ; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54 (8) 2665-2673
  CrossrefPubMedGoogle Scholar
• 43 Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011; 63 (2) 195-202
  CrossrefPubMedGoogle Scholar
• 44 Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011; Sep 8. doi:10.1002/acr.20627
  PubMedGoogle Scholar
• 45 Di Minno MN, Tufano A, Rusolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 2010; 16 (48) 6119-6122
  CrossrefPubMedGoogle Scholar
• 46 Seitz M, Reichenbach S, Möller B, Zwahlen M, Villiger PM, Dufour JF. Hepatoprotective effect of tumor necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010; 69 (6) 1148-1150
  CrossrefPubMedGoogle Scholar
• 47 Di Minno MND, Iervolino S, Peluso R , et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis on TNF-α blockers. J Rheumatol 2011; ;in press. DOI: 10.3899/jrheum.111391
  PubMedGoogle Scholar
• 48 Di Minno MN, Tremoli E, Coppola A, Lupoli R, Di Minno G. Homocysteine and arterial thrombosis: challenge and opportunity. Thromb Haemost 2010; 103 (5) 942-961
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol 2001; 30 (5) 305-307
  CrossrefPubMedGoogle Scholar
• 50 Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19 (6) 1368-1377
  CrossrefPubMedGoogle Scholar
• 51 Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981; 40 (1) 66-69
  CrossrefPubMedGoogle Scholar
• 52 Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012; 39: 334-336
  CrossrefPubMedGoogle Scholar
• 53 Kimhi O, Caspi D, Bornstein NM , et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36 (4) 203-209
  CrossrefPubMedGoogle Scholar
• 54 Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA , et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57 (2) 287-293
  CrossrefPubMedGoogle Scholar
• 55 Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57 (6) 1074-1080
  CrossrefPubMedGoogle Scholar
• 56 Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 2011; ; In press
  PubMedGoogle Scholar
• 57 Shoenfeld Y, Gerli R, Doria A , et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112 (21) 3337-3347
  CrossrefPubMedGoogle Scholar
• 58 Eder L, Zisman D, Barzilai M , et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35 (5) 877-882
  PubMedGoogle Scholar
• 59 Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G ; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31: 705-712
  CrossrefPubMedGoogle Scholar
• 60 Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40 (10) 1868-1872
  CrossrefPubMedGoogle Scholar
• 61 Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68 (7) 1131-1135
  CrossrefPubMedGoogle Scholar
• 62 Jamnitski A, Visman IM, Peters MJ, Boers M, Dijkmans BA, Nurmohamed MT. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 2011; 70 (5) 875-876
  CrossrefPubMedGoogle Scholar
• 63 Buckley C, Cavill C, Taylor G , et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol 2010; 37 (10) 2141-2144
  CrossrefPubMedGoogle Scholar
• 64 Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27 (5) 1247-1250
  PubMedGoogle Scholar
• 65 Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369 (9570) 1379-1390
  CrossrefPubMedGoogle Scholar
• 66 Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011; 63 (4) 550-556 DOI: 10.1002/acr.20408.
  CrossrefPubMedGoogle Scholar
• 67 Peters MJ, Visman I, Nielen MM , et al. Ankylosing spondylitis: a risk factor for myocardial infarction?. Ann Rheum Dis 2010; 69 (3) 579-581
  CrossrefPubMedGoogle Scholar
• 68 Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33 (11) 2167-2172
  PubMedGoogle Scholar
• 69 Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63 (4) 557-563
  CrossrefPubMedGoogle Scholar
• 70 Başkan BM, Sivas F, Aktekin LA, Doğan YP, Ozoran K, Bodur H. Serum homocysteine level in patients with ankylosing spondylitis. Rheumatol Int 2009; 29 (12) 1435-1439
  CrossrefPubMedGoogle Scholar
• 71 Gonzalez-Lopez L, Sanchez-Hernandez JD, Aguilar-Chavez EA , et al. Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables. Rheumatol Int 2008; 28 (12) 1223-1228
  CrossrefPubMedGoogle Scholar
• 72 Wei JC, Jan MS, Yu CT , et al. Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26 (5) 739-742
  CrossrefPubMedGoogle Scholar
• 73 Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109 (2) 171-176
  CrossrefPubMedGoogle Scholar
• 74 Papadakis JA, Sidiropoulos PI, Karvounaris SA , et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009; 27 (2) 292-298
  PubMedGoogle Scholar
• 75 van Halm VP, van Denderen JC, Peters MJ , et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65 (11) 1473-1477
  CrossrefPubMedGoogle Scholar
• 76 van Eijk IC, de Vries MK, Levels JH , et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60 (5) 1324-1330
  CrossrefPubMedGoogle Scholar
• 77 Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med 1989; 321 (19) 1311-1316
  CrossrefPubMedGoogle Scholar
• 78 Kemény-Beke Á, Gesztelyi R, Bodnár N , et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine 2011; 78 (2) 184-187
  CrossrefPubMedGoogle Scholar
• 79 Erre GL, Sanna P, Zinellu A , et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 2011; 30 (1) 21-27
  CrossrefPubMedGoogle Scholar
• 80 Sari I, Okan T, Akar S , et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45 (3) 283-286
  CrossrefPubMedGoogle Scholar
• 81 van Eijk IC, Peters MJ, Serné EH , et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009; 68 (3) 362-366
  CrossrefPubMedGoogle Scholar
• 82 Mathieu S, Joly H, Baron G , et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008; 47 (8) 1203-1207
  CrossrefPubMedGoogle Scholar
• 83 Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA , et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88 (6) 358-365
  CrossrefPubMedGoogle Scholar
• 84 Lautermann D, Braun J. Ankylosing spondylitis—cardiac manifestations. Clin Exp Rheumatol 2002; 20 (6, Suppl 28) S11-S15
  PubMedGoogle Scholar
• 85 Vinsonneau U, Brondex A, Mansourati J , et al. Cardiovascular disease in patients with spondyloarthropathies. Joint Bone Spine 2008; 75 (1) 18-21
  CrossrefPubMedGoogle Scholar
• 86 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286 (8) 954-959
  CrossrefPubMedGoogle Scholar
• 87 Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153 (4) 477-484
  CrossrefPubMedGoogle Scholar
• 88 Gislason GH, Rasmussen JN, Abildstrom SZ , et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169 (2) 141-149
  CrossrefPubMedGoogle Scholar
• 89 Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006; 164 (9) 881-889
  CrossrefPubMedGoogle Scholar
• 90 White WB, West CR, Borer JS , et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99 (1) 91-98
  CrossrefPubMedGoogle Scholar
• 91 Solomon DH, Avorn J, Katz JN , et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54 (12) 3790-3798
  CrossrefPubMedGoogle Scholar
• 92 Edwards CJ, Arden NK, Fisher D , et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005; 44 (11) 1394-1398
  CrossrefPubMedGoogle Scholar
• 93 Westlake SL, Colebatch AN, Baird J , et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49 (2) 295-307
  CrossrefPubMedGoogle Scholar
• 94 Micha R, Imamura F, Wyler von Ballmoos M , et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108 (9) 1362-1370
  CrossrefPubMedGoogle Scholar
• 95 Moreland LW, Schiff MH, Baumgartner SW , et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130 (6) 478-486
  CrossrefPubMedGoogle Scholar
• 96 Vis M, Nurmohamed MT, Wolbink G , et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; (32) 252-255
  PubMedGoogle Scholar
• 97 Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006; 365 (1–2) 143-148
  CrossrefPubMedGoogle Scholar
• 98 Schimmel EK, Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exp Rheumatol 2009; 27 (3) 446-451
  PubMedGoogle Scholar
• 99 Macías I, García-Pérez S, Ruiz-Tudela M, Medina F, Chozas N, Girón-González JA. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (11) 2102-2108
  PubMedGoogle Scholar
• 100 Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103 (13) 1813-1818
  CrossrefPubMedGoogle Scholar
• 101 Hürlimann D, Forster A, Noll G , et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106 (17) 2184-2187
  CrossrefPubMedGoogle Scholar
• 102 Mazzoccoli G, Notarsanto I, de Pinto GD , et al. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 2010; 5 (6) 495-500
  CrossrefPubMedGoogle Scholar
• 103 Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177 (1) 113-118
  CrossrefPubMedGoogle Scholar
• 104 Sidiropoulos PI, Siakka P, Pagonidis K , et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38 (1) 6-10
  CrossrefPubMedGoogle Scholar
• 105 Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010; 55 (2) 333-338
  CrossrefPubMedGoogle Scholar
• 106 Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44 (11) 1428-1432
  CrossrefPubMedGoogle Scholar
• 107 Del Porto F, Laganà B, Lai S , et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (7) 1111-1115
  CrossrefPubMedGoogle Scholar
• 108 Tam LS, Li EK, Shang Q , et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 2011; 70 (4) 705-706
  CrossrefPubMedGoogle Scholar
• 109 Jacobsson LT, Turesson C, Gülfe A , et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (7) 1213-1218
  PubMedGoogle Scholar
• 110 Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP ; British Society for Rheumatology Biologics Register Control Centre Consortium ; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56 (9) 2905-2912
  CrossrefPubMedGoogle Scholar
• 111 Westlake SL, Colebatch AN, Baird J , et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011; 50: 518-531
  CrossrefPubMedGoogle Scholar
• 112 Panoulas VF, Douglas KM, Milionis HJ , et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (9) 1477-1482
  CrossrefPubMedGoogle Scholar
• 113 Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70 (1) 8-14
  CrossrefPubMedGoogle Scholar
• 114 Conroy RM, Pyörälä K, Fitzgerald AP , et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24 (11) 987-1003
  CrossrefPubMedGoogle Scholar
• 115 Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18) 1837-1847
  CrossrefPubMedGoogle Scholar
• 116 Chung CP, Oeser A, Avalos I , et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8 (6) R186
  CrossrefPubMedGoogle Scholar
• 117 Peters MJ, Symmons DP, McCarey D , et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69 (2) 325-331
  CrossrefPubMedGoogle Scholar
• 118 National Institute for Health and Clinical Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Available at: http://www.nice.org.uk/media/F72/5C/BiologicDrugsUpdateAug2011.pdf . Accessed Aug 2011
  PubMedGoogle Scholar
• 119 Iervolino S, Di Minno MND, Peluso R , et al. Predictors of early minimal disease activity in Psoriatic Arthritis patients treated with TNF-α blockers. J Rheumatol 2012; ;in press. DOI: 10.3899/jrheum.110763
  PubMedGoogle Scholar